Business
Crescita Reports Q4 and Fiscal 2025 Results
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or th...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"Crescita Reports Q4 and Fiscal 2025 Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n.bwmarginl1 { margin-left: 30px }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl3 { padding-left: 15px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth64 { width: 64% }\n.bwwidth7 { width: 7% }\n.bwwidth72 { width: 72% }\n.bwwidth9 { width: 9% }\n \n\n\n\n Crescita Therapeutics Inc. (\n \n TSX: CTX\n \n and\n \n OTC US: CRRTF\n \n ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025 (“Q4-2025” and “F2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.\n \n\n\n Financial Highlights\n \n\n\n\n Q4-2025 vs. Q4-2024\n \n 2\n \n\n\n\n\n Revenue was $5,955 compared to $6,902, down $947;\n \n\n Gross profit was $3,239 compared to $2,807, up $432;\n \n\n Operating expenses were $3,620 compared to $3,075, up $545;\n \n\n Net loss was $(711) compared to a net loss of $(162), up $549;\n \n\n Adjusted EBITDA\n \n\n 1\n \n\n was $70 compared to $151, down $81.\n \n\n\n\n F2025 vs. F2024\n \n 2\n \n\n\n\n\n Revenue was $21,118 compared to $19,580, up $1,538;\n \n\n Gross profit was $11,109 compared to $8,990, up $2,119;\n \n\n Operating expenses were $12,131 compared to $12,205, down $74;\n \n\n Net loss was $(92) compared to a net loss of $(2,750), up $2,658;\n \n\n Adjusted EBITDA\n \n 1\n \n was $617 comp...